Align 10-Q: Q3 EPS $1.90, Gross Margin 68.7%, $43.1M UK VAT Charge Booked
ALGN sits 27% above its 52-week low of $130.23 on elevated volume (1.8× avg).
Summary
Align's Q3 10-Q confirms $1.015 billion revenue and $1.90 diluted EPS, and adds a $43.1 million UK VAT accrual, a new $35-$37 million restructuring, and the Ninth Circuit's revival of the City Smiles antitrust case.
Key Events · Earnings and Guidance · ALGN
-
Q3 Revenue $1.015B, EPS $1.90
Revenue rose 1.9% year-over-year to $1,014.8 million, and diluted EPS reached $1.90 versus $0.78 a year earlier, with net income of $135.0 million.
-
Gross Margin Expands to 68.7%
Gross margin improved from 64.2% to 68.7%, driven by operational efficiencies, tariff refunds and roll-off of accelerated depreciation, partly offset by lower clear aligner ASPs.
-
$43.1M UK VAT Liability Booked
After the Upper Tribunal held on July 7, 2026 that aligners are not dental prostheses, Align recorded a $43.1 million probable liability including interest and is appealing to the Court of Appeal.
-
New 2026 Restructuring, $35-37M Expected
A Q3 2026 workforce realignment carries $35.0-$37.0 million of expected charges; $28.5 million was recorded to date, with $20.7 million unpaid at quarter end.
Analysis · ALGN · Industrial Applications And Services
The quarter itself was already public via the October 28 8-K, but the full 10-Q fills in what that release did not. A $43.1 million UK VAT liability is now booked as a probable loss after the Upper Tribunal ruled aligners are not dental prostheses; a fresh 2026 restructuring is expected to cost $35.0-$37.0 million; and the Ninth Circuit revived the City Smiles antitrust class action on October 5. Against those charges, the core business improved: gross margin rose to 68.7% from 64.2%, and nine-month operating cash flow reached $526.7 million versus $370.0 million a year ago. With $1,145 million of cash and no borrowings drawn on the $300 million revolver, the charges are absorbable, but the VAT appeal and the remanded antitrust case remain open-ended.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALGN was trading at $164.90 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $11.7B. The 52-week trading range was $130.23 to $200.44. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.